TrialAntimicrobial agents and chemotherapy2007

Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.

Daniel J Tenney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.